Amlodipine: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: Anti-Hypoertensive (dihydropyridine-CCB) | *Type: Anti-Hypoertensive (dihydropyridine-CCB) | ||
*Dosage Forms: 2. | *Dosage Forms: tablet | ||
*Dosage Strengths: 2.5mg, 5mg, 10mg | |||
*Routes of Administration: PO | |||
*Common Trade Names: Norvasc | *Common Trade Names: Norvasc | ||
Revision as of 19:40, 11 October 2017
General
- Type: Anti-Hypoertensive (dihydropyridine-CCB)
- Dosage Forms: tablet
- Dosage Strengths: 2.5mg, 5mg, 10mg
- Routes of Administration: PO
- Common Trade Names: Norvasc
Adult Dosing
- hypertension
- 5-10mg PO qDaily
- Start: 5mg PO qDaily for intial antihypertesnive, do 2.5 if elderly or 2nd line drug
Pediatric Dosing
- hypertension
- 2.5-5mg PO qDaily
Special Populations
- Pregnancy Rating: C
- Lactation: Safety Unknown
- Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
- Hepatic Dosing
- Adult: Start at 2.5mg qDaily
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Severe CAD, AS, CHF
- Re-dose/Caution: Elderly/Hepatic Impairment
Adverse Reactions
Serious
- Angina, MI, Hypotension, Hepatitis, Erythema multiforme
Common
- Peripheral edema, fatigue, palpitations, dizziness, nausea, flushing, eczematous eruptions
Pharmacology
- Half-life: 30-50h
- Metabolism: liver extensively; CYP450: 3A4
- Excretion: urine 59-62% (5-10% unchanged), bile/feces 20-25%
- Mechanism of Action: CCB-dihydropyridine